The Incidence of Invasive Fungal Infections in Patients With AML Treated With a Hypomethylating Agent
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved..
BACKGROUND: Newly diagnosed patients with acute myeloid leukemia (AML) who receive induction with a hypomethylating agent (HMA) are often neutropenic with an increased risk for invasive fungal infections (IFIs). This study analyzed the incidence and risk factors for IFIs in these patients, evaluated clinical patterns in antifungal prophylaxis, and assessed the diagnostic utility of tests in this setting.
PATIENTS AND METHODS: We studied 117 newly diagnosed patients with AML treated with HMAs at our center, divided into groups based on concern for IFI (cIFI: all possible, probable, and proven IFIs) versus no concern for IFI. The Fisher exact test compared patients with cIFI versus without, and a multivariable logistic regression model estimated odds for cIFI.
RESULTS: Sixty-seven (57%) patients had cIFI, with 48 possible IFIs, 17 probable, and 2 proven cases. There was no difference in incidence based on home zip code, but the presence of chronic obstructive pulmonary disease was highly associated with cIFI (P = .001), as was male gender (P = .01). Neutropenia at treatment initiation was borderline in significance (P = .08). In diagnostics, 9% of patients had positive serum fungal markers, and 30 patients underwent bronchoscopy, with only 27% of cases yielding positive results. There was a difference in treatment regimens between patients receiving antifungal prophylaxis with mold coverage versus without mold coverage with respect to cIFI (P = .04).
CONCLUSIONS: cIFI in patients with AML treated with HMAs remains significant, especially in males and those with chronic obstructive pulmonary disease, who were found to be at higher risk. This may prompt clinicians to consider anti-mold prophylaxis in this setting.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Clinical lymphoma, myeloma & leukemia - 21(2021), 1 vom: 30. Jan., Seite e76-e83 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ozga, Michael [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute myeloid leukemia |
|---|
| Anmerkungen: |
Date Completed 15.12.2021 Date Revised 15.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.clml.2020.08.013 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM31493670X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM31493670X | ||
| 003 | DE-627 | ||
| 005 | 20231225153823.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clml.2020.08.013 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1049.xml |
| 035 | |a (DE-627)NLM31493670X | ||
| 035 | |a (NLM)32921593 | ||
| 035 | |a (PII)S2152-2650(20)30429-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ozga, Michael |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Incidence of Invasive Fungal Infections in Patients With AML Treated With a Hypomethylating Agent |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.12.2021 | ||
| 500 | |a Date Revised 15.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Newly diagnosed patients with acute myeloid leukemia (AML) who receive induction with a hypomethylating agent (HMA) are often neutropenic with an increased risk for invasive fungal infections (IFIs). This study analyzed the incidence and risk factors for IFIs in these patients, evaluated clinical patterns in antifungal prophylaxis, and assessed the diagnostic utility of tests in this setting | ||
| 520 | |a PATIENTS AND METHODS: We studied 117 newly diagnosed patients with AML treated with HMAs at our center, divided into groups based on concern for IFI (cIFI: all possible, probable, and proven IFIs) versus no concern for IFI. The Fisher exact test compared patients with cIFI versus without, and a multivariable logistic regression model estimated odds for cIFI | ||
| 520 | |a RESULTS: Sixty-seven (57%) patients had cIFI, with 48 possible IFIs, 17 probable, and 2 proven cases. There was no difference in incidence based on home zip code, but the presence of chronic obstructive pulmonary disease was highly associated with cIFI (P = .001), as was male gender (P = .01). Neutropenia at treatment initiation was borderline in significance (P = .08). In diagnostics, 9% of patients had positive serum fungal markers, and 30 patients underwent bronchoscopy, with only 27% of cases yielding positive results. There was a difference in treatment regimens between patients receiving antifungal prophylaxis with mold coverage versus without mold coverage with respect to cIFI (P = .04) | ||
| 520 | |a CONCLUSIONS: cIFI in patients with AML treated with HMAs remains significant, especially in males and those with chronic obstructive pulmonary disease, who were found to be at higher risk. This may prompt clinicians to consider anti-mold prophylaxis in this setting | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Acute myeloid leukemia | |
| 650 | 4 | |a Anti-mold azoles | |
| 650 | 4 | |a Antifungal prophylaxis | |
| 650 | 4 | |a Decitabine | |
| 650 | 4 | |a Risk stratification | |
| 650 | 7 | |a Antifungal Agents |2 NLM | |
| 700 | 1 | |a Huang, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Blachly, James S |e verfasserin |4 aut | |
| 700 | 1 | |a Grieselhuber, Nicole R |e verfasserin |4 aut | |
| 700 | 1 | |a Wall, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Larkin, Karilyn |e verfasserin |4 aut | |
| 700 | 1 | |a Haque, Tamanna |e verfasserin |4 aut | |
| 700 | 1 | |a Walker, Alison R |e verfasserin |4 aut | |
| 700 | 1 | |a Bhatnagar, Bhavana |e verfasserin |4 aut | |
| 700 | 1 | |a Behbehani, Gregory |e verfasserin |4 aut | |
| 700 | 1 | |a Vasu, Sumithira |e verfasserin |4 aut | |
| 700 | 1 | |a Maakaron, Joseph E |e verfasserin |4 aut | |
| 700 | 1 | |a Lustberg, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Mims, Alice S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical lymphoma, myeloma & leukemia |d 2010 |g 21(2021), 1 vom: 30. Jan., Seite e76-e83 |w (DE-627)NLM195738748 |x 2152-2669 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2021 |g number:1 |g day:30 |g month:01 |g pages:e76-e83 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clml.2020.08.013 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2021 |e 1 |b 30 |c 01 |h e76-e83 | ||